Drug Profile
HPV E6 TCR T cells - TCRCure Biotech
Alternative Names: HPV E6-specific TCR-T cells - TCRCure BiotechLatest Information Update: 06 Jul 2023
Price :
$50
*
At a glance
- Originator TCRCure Biopharma
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Head and neck cancer
- No development reported Cervical cancer
Most Recent Events
- 02 Jun 2023 Efficacy, safety and pharmacokinetics data from a phase I trial in Cervical-cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 26 Nov 2021 Phase-I development in Cervical-cancer is ongoing in China (NCT04139057)
- 28 Oct 2021 No recent reports of development identified for phase-I development in Cervical-cancer(Metastatic disease, Recurrent) in China (Parenteral, Infusion)